Multi-drug-resistant tuberculosis cost-effectiveness of therapy
|
Multi-drug-resistant tuberculosis Microchapters |
|
Differentiating Multi-drug-resistant tuberculosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Multi-drug-resistant tuberculosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
FDA on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
CDC on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
Multi-drug-resistant tuberculosis cost-effectiveness of therapy in the news |
|
Blogs on Multi-drug-resistant tuberculosis cost-effectiveness of therapy |
|
Directions to Hospitals Treating Multi-drug-resistant tuberculosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Cost-effectiveness of therapy
- The average cost of treating a person with TB disease increases with greater resistance.
- Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). [1]
- When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.[1]
 |